We are offering our innovative "human robust, reproducible & reliable respiratory platform" that is reconstructed from normal and diseased human lung tissue, to dramatically enhance and accelerate respiratory drug discovery.
SCROLL
Research paper on the illuminating the evolutionary and epidemic dynamics of XBB variant of G2P-Japan, co-authored by HiLung members, was published in the journal “Nature Communications” on 16 May.
Research paper on the elucidating the evolutionary patterns of Omicron subvariants of G2P-Japan, co-authored by HiLung members, was published in the journal “Nature Communications” on 11 May.
We are joining [2023 RIKEN BDR-CuSTOM Joint Organoid Symposium], KOBE from February 15th -17th.
Selected as Top Drug Discovery Development Solutions Provider in APAC 2022 by Pharma Tech Outlook.
New Year’s Holiday Closing Notice
We have experience in dramatically accelerating the drug discovery process for respiratory diseases based on our extensive experience and recent findings on "lung stem cell biology", including those based on human iPS cell differentiation technology. Our services will assist in efficient preclinical discovery of highly effective therapeutic drug candidates based on well-founded human pathophysiology models we have developed. We will continue to adapt and optimize our human lung model servicing and packaging to better fit our clients' needs, while establishing the additional science and the track record ultimately needed to bring about cell and tissue therapies for respiratory organs.
VIEW MOREOur core technologies and engineering have for the first time enabled a very reliable mass production of human respiratory epithelial cells that essentially replicates human biology. We are applying this core technology to replicate disease pathophysiology for drug discovery purposes and normal physiology for toxicity studies, and will further strengthen it to enable cell therapy and tissue transplantation purposes.
VIEW MOREWe are not currently recruiting.